Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | AutoSCT vs CAR-T for patients with relapsed LBCL in PR: the role of total metabolic tumor volume

Paolo Strati • 8 Sep 2023

SOHO 2023

Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on a recent publication assessing the use of total metabolic tumor volume (TMTV) as a marker of subsequent response to autologous stem cell transplant (autoSCT) or CAR-T therapy, in patients with relapsed large B-cell lymphoma (LBCL) who experience a partial response (PR) with bridging therapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

BTK inhibitors in the treatment of DLBCL: trials investigating these agents

Paolo Strati • 10 Dec 2023

Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL

Paolo Strati • 10 Dec 2023

Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL

Paolo Strati • 10 Dec 2023

Autologous SIRPα- low macrophages (SIRPant-M) enhance immune anti-tumor activity in R/R NHL

Paolo Strati • 10 Dec 2023

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024